May 2, 2022
Cancer Immunotherapy Developers in Asia Explore Diverse Approaches
We hunt virus by harnessing the power of a patient’s own immune system to eliminate Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), with proven clinical safety and efficacy.
Our proprietary personalized TCR-T cell therapy has been applied in clinics for
• HBV related HCC
• Recurrent HCC post liver transplant • Chronic HBV infection
Our library of HBV-specific TCRs covers about 80% of the patient population with a broad range of HLA types, particularly those predominant in Asia where HBV is prevalent.
Transient expression of our TCR on T-cells confers enhanced safety features which allows for a conservative dose escalation design in clinical trials and future use for other cancer treatment.
A comprehensive facility for the manufacturing of our proprietary product for clinical use in compliance with Good-Manufacturing-Practice (GMP) guidelines.
A safer personalized treatment providing an approximately 3-fold increase in survival time compared to existing standard of care medication for liver cancer patients in our Phase 1 studies.
Our TCR-T cell therapy harnesses the patient’s own immune system to fight against viral infections and related cancers.
We are conducting ongoing clinical trials against hepatocellular carcinoma (HCC) to evaluate the safety and efficiacy of our TCR-T cells.
December 23, 2021
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
November 29, 2021
Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List